Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease : results from nationwide Swedish registers
Background: Comparisons of second-line anti-tumour necrosis factor (TNF) agents and vedolizumab are sparse. Aim: To evaluate the effectiveness of anti-TNF agents compared to vedolizumab as second-line biologics in inflammatory bowel disease (IBD). Methods: A propensity score-matched cohort was created using Swedish nationwide registers. Patients with Crohn's disease or ulcerative colitis, exposed